Immunity from the measles vaccine declines significantly over time, with 18.1% of recipients lacking detectable antibodies 23 years after vaccination.
A study published Nov. 3 in eClinicalMedicine, the open access journal of The Lancet, by researchers from the University of Miami analyzed 18 studies involving 23,236 vaccinated individuals across 10 countries. The researchers found that the overall pooled seropositivity rate was 87.8%, with higher rates among those who received two or more doses (88.8%) compared to a single dose (84.3%).
Immunity declined steadily over time: 7.1% lacked antibodies 10 years after vaccination, 13% at 15 years, and 18.1% at 23 years or later. Each additional year post-vaccination was linked to a 5% decrease in the odds of being seropositive.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
